SCHEMBL5898545

SCHEMBL5898545

CCC(O)(CCC(N)=O)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
CYP2C19 P33261 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CHRM3 P20309 2/20 0.39
KIF11 P52732 4/20 0.39
KCNN4 O15554 3/20 0.39
DRD2 P14416 1/20 0.38
OPRM1 P35372 1/20 0.38
DRD3 P35462 1/20 0.38
LMNA P02545 2/20 0.38
HIF1A Q16665 1/20 0.38
CHRM2 P08172 1/20 0.38
CYP2D6 P10635 1/20 0.38
CHRM1 P11229 1/20 0.38
KCNH2 Q12809 1/20 0.38
HTT P42858 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8360630 0.83 MAPT (0.43) MAPTKMT2ACYP2C19CYP1A2CYP2C9
SCHEMBL8363513 0.83 KCNN4 (0.49) KCNN4KDM4E
SCHEMBL5898567 0.83 ALDH1A1 (0.38) KMT2ACYP2C19CYP1A2CYP2C9KIF11
SCHEMBL6266034 0.83 CES2 (0.39) KMT2ACYP2C19CYP1A2KIF11LMNA
SCHEMBL5898588 0.82 MAPT (0.46) MAPTKMT2ACYP2C19CYP1A2CYP2C9
SCHEMBL17594854 0.81 CYP1A2 (0.61) MAPTKMT2ACYP2C19CYP1A2CYP2C9
SCHEMBL17064282 0.81 MAPT (0.44) MAPTKMT2ACYP2C19CYP1A2CHRM3
SCHEMBL4055699 0.79 CYP2C19 (0.50) MAPTKMT2ACYP2C19CYP1A2CHRM3
SCHEMBL23014014 0.77 CYP2C19 (0.48) KMT2ACYP2C19CYP1A2CYP2C9CHRM3
SCHEMBL4307361 0.77 CYP2C19 (0.56) KMT2ACYP2C19CYP1A2CYP2C9CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230414566-A1 ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES UNIVERSITY OF HOUSTON SYSTEM (US) 2023-12-28 US disclosed
US-11806333-B2 Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures UNIVERSITY OF HOUSTON SYSTEM (US) 2023-11-07 US disclosed
US-20200360342-A1 ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES UNIVERSITY OF HOUSTON SYSTEM (US) 2020-11-19 US disclosed
US-20060287397-A1 Dl-hydroxy-alkyl-phenylamides having anticonvulsive activity MEZA TOLEDO SERGIO E 2006-12-21 US disclosed
US-5463125-A 3-hydroxy-3-phenylpentamide SANDOVAL GUILLERMO C (MX) 1995-10-31 US disclosed
US-5463125-A 3-hydroxy-3-phenylpentamide SANDOVAL GUILLERMO C (MX) 1995-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200360342-A1 ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES AADAC, GABRB2, GABARAPL2 MAPT 1500/4885KMT2A 1290/4885CYP2C19 148/4885
US-20060287397-A1 Dl-hydroxy-alkyl-phenylamides having anticonvulsive activity GABRB2, HRH3, HRH4 MAPT 2331/4885KMT2A 211/4885CYP2C19 1452/4885
US-20230414566-A1 ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES AADAC, GABRB2, GABARAPL2 MAPT 1500/4885KMT2A 1290/4885CYP2C19 148/4885
US-11806333-B2 Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures AADAC, GABRB2, GABARAPL2 MAPT 1500/4885KMT2A 1290/4885CYP2C19 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.